Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer

Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer

Trastuzumab-based treatment has dramatically improved the outcomes of HER2-positive (HER2+) metastatic breast cancer (MBC) patients, with some patients achieving prolonged survival times. In this study, we aim to identify factors that are associated with long-term survival. Patients with HER2+ MBC t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast cancer research and treatment 2016-09, Vol.159 (2), p.367-374
Hauptverfasser: Harano, K., Lei, X., Gonzalez-Angulo, A. M., Murthy, R. K., Valero, V., Mittendorf, E. A., Ueno, N. T., Hortobagyi, G. N., Chavez-MacGregor, M.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Analysis
Antineoplastic Agents, Immunological - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - surgery
Cancer metastasis
Cancer patients
Cancer research
Cancer therapies
Care and treatment
Disease-Free Survival
Epidemiology
Female
Humans
Mastectomy
Medical research
Medicine
Medicine & Public Health
Metastasis
Middle Aged
Neoplasm Metastasis
Oncology
Pathology
Patient outcomes
Receptor, ErbB-2 - metabolism
Retrospective Studies
Surgery
Survival Analysis
Trastuzumab - therapeutic use
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Trastuzumab-based treatment has dramatically improved the outcomes of HER2-positive (HER2+) metastatic breast cancer (MBC) patients, with some patients achieving prolonged survival times. In this study, we aim to identify factors that are associated with long-term survival. Patients with HER2+ MBC treated with anti-HER2 target therapy were identified. Patients were grouped according to overall survival (OS) and categorized as long-term survivors (LTS, OS ≥ 5 years), or non-long-term survivors (non-LTS, OS 
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-016-3933-6